ArticleJournal of clinical medicine2019
Rifabutin-Based Rescue Therapy for
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Third-line and rescue therapy for refractoryWorld journal of gastroenterology · 2023Pooled it
- Chemoprevention of gastric cancer development afterWorld journal of gastroenterology · 2020Pooled it
- Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance.BMC gastroenterology · 2025Trial
- Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments forWorld journal of gastroenterology · 2019Trial
- Review
- Third-Line and Later Susceptibility-GuidedJournal of clinical medicine · 2026Article
- Novel Drug Delivery Systems for CombatingArchives of Razi Institute · 2024Review
- Review
- Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies forTropical medicine and infectious disease · 2023Review
- Treatment of refractoryFrontiers in microbiology · 2022Review
- Revisiting Therapeutic Strategies forMolecules (Basel, Switzerland) · 2021Review
- Review
- Clinical Relevance ofJournal of clinical medicine · 2021Review
- Rescue Therapies forAntibiotics (Basel, Switzerland) · 2021Article
- Rifabutin for the Treatment ofPathogens (Basel, Switzerland) · 2020Review
- Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.Applied microbiology and biotechnology · 2020Review
- Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-ResistantOpen forum infectious diseases · 2020Review
- BestAntibiotics (Basel, Switzerland) · 2020Review
- Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains.BMC gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most commonly used regimens fail to eradicate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.